PATH vs SBFMW · P/E 19, rev $1.61B vs rev $34.9M
Uipath Inc (PATH) versus Sunshine Biopharma Inc. Warrant (SBFMW) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Sunshine Biopharma Inc. Warrant (SBFMW) common stock listed on NASDAQ.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported SBFMW revenue for 2024-12-31 was $34.9M. Net income was -$5.1M. Revenue was up 44.7% from 2023-12-31 to 2024-12-31. SBFMW currently screens at market cap $0.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. SBFMW currently screens at market cap $0.
Not investment advice. Open the PATH and SBFMW stock pages for the full models.
Not investment advice.